1. Home
  2. RBBN vs AGEN Comparison

RBBN vs AGEN Comparison

Compare RBBN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$1.54

Market Cap

355.8M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

SELL

Current Price

$6.97

Market Cap

335.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RBBN
AGEN
Founded
1997
1994
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
355.8M
335.6M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
RBBN
AGEN
Price
$1.54
$6.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$3.08
★ $26.33
AVG Volume (30 Days)
★ 1.4M
777.3K
Earning Date
10-27-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 170.97
100.00
EPS
N/A
★ 0.96
Revenue
N/A
★ $42,877,086.00
Revenue This Year
N/A
$9.64
Revenue Next Year
$5.15
N/A
P/E Ratio
★ N/A
$6.94
Revenue Growth
N/A
★ 89.95
52 Week Low
$1.28
$2.71
52 Week High
$3.41
$10.19

Technical Indicators

Market Signals
Indicator
RBBN
AGEN
Relative Strength Index (RSI) 49.66 45.16
Support Level $1.55 $6.66
Resistance Level $1.87 $8.64
Average True Range (ATR) 0.13 0.43
MACD 0.03 0.04
Stochastic Oscillator 70.46 51.54

Price Performance

Historical Comparison
RBBN
AGEN

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: